Physician profile
Michael E Salacz
NPI 1235178872
$597.32
in general payments reported to CMS, 2019-2025
14 companies · $597 in 2025
The $597 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549 · Education: $48.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.12 |
| Education | $48.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $178.57 | 2025 | Signia |
| Daiichi Sankyo INC. | $126.08 | 2025 | Enhertu, Injectafer, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $71.32 | 2025 | Opdivo |
| Beone Medicines USA, INC. | $35.14 | 2025 | Tevimbra |
| Abbvie INC. | $33.79 | 2025 | |
| Caris Mpi, INC. | $28.77 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Welireg |
| Stemline Therapeutics INC. | $25.35 | 2025 | Orserdu |
| Genzyme Corporation | $19.00 | 2025 | |
| Pharmacosmos Therapeutics INC. | $18.83 | 2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $17.65 | 2025 | |
| Pfizer INC. | $17.12 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salacz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.